7JUA

Crystal structure of the second heterocyclization domain of yersiniabactin synthetase at 2.35 A resolution

7JUA の概要

• エントリーDOI: 10.2210/pdb7jua/pdb
• 関連するPDBエントリー: 7JTJ
• 分子名称: Irp2 protein, SODIUM ION, 2-(2-METHOXYETHOXY)ETHANOL, ... (4 entities in total)
• 機能のキーワード: heterocyclization domain, biosynthetic protein
• 由来する生物種: Yersinia pestis
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 51971.90

構造登録者

Xia, Y.,Soule, J.,Dowling, D.P. (登録日: 2020-08-19, 公開日: 2021-09-22, 最終更新日: 2023-10-18)

主引用文献

Gnann, A.D.,Xia, Y.,Soule, J.,Barthelemy, C.,Mawani, J.S.,Musoke, S.N.,Castellano, B.M.,Brignole, E.J.,Frueh, D.P.,Dowling, D.P.
High-resolution structures of a siderophore-producing cyclization domain from Yersinia pestis offer a refined proposal of substrate binding.
J.Biol.Chem., :102454-102454, 2022

PubMed Abstract: Nonribosomal peptide synthetase heterocyclization (Cy) domains generate biologically important oxazoline/thiazoline groups found in natural products, including pharmaceuticals and virulence factors such as some siderophores. Cy domains catalyze consecutive condensation and cyclodehydration reactions, although the mechanism is unknown. To better understand Cy domain catalysis, here we report the crystal structure of the second Cy domain (Cy2) of yersiniabactin synthetase from the causative agent of the plague, Yersinia pestis. Our high-resolution structure of Cy2 adopts a conformation that enables exploration of interactions with the extended thiazoline-containing cyclodehydration intermediate and the acceptor carrier protein (CP) to which it is tethered. We also report complementary electrostatic interfaces between Cy2 and its donor CP that mediate donor binding. Finally, we explored domain flexibility through normal mode analysis and identified small-molecule fragment-binding sites that may inform future antibiotic design targeting Cy function. Our results suggest how CP binding may influence global Cy conformations, with consequences for active-site remodeling to facilitate the separate condensation and cyclodehydration steps as well as potential inhibitor development.

PubMed: 36063993
DOI: 10.1016/j.jbc.2022.102454

実験手法

X-RAY DIFFRACTION (2.35 Å)